BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22179832)

  • 1. Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens.
    Dart DA; Brooke GN; Sita-Lumsden A; Waxman J; Bevan CL
    Oncogene; 2012 Oct; 31(43):4588-98. PubMed ID: 22179832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.
    Dart DA; Spencer-Dene B; Gamble SC; Waxman J; Bevan CL
    Endocr Relat Cancer; 2009 Dec; 16(4):1157-69. PubMed ID: 19635783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity.
    Gamble SC; Chotai D; Odontiadis M; Dart DA; Brooke GN; Powell SM; Reebye V; Varela-Carver A; Kawano Y; Waxman J; Bevan CL
    Oncogene; 2007 Mar; 26(12):1757-68. PubMed ID: 16964284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.
    Dai Y; Ngo D; Jacob J; Forman LW; Faller DV
    Carcinogenesis; 2008 Sep; 29(9):1725-33. PubMed ID: 18487222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer.
    Fletcher CE; Dart DA; Sita-Lumsden A; Cheng H; Rennie PS; Bevan CL
    Hum Mol Genet; 2012 Jul; 21(14):3112-27. PubMed ID: 22505583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells.
    Jia L; Shen HC; Wantroba M; Khalid O; Liang G; Wang Q; Gentzschein E; Pinski JK; Stanczyk FZ; Jones PA; Coetzee GA
    Mol Cell Biol; 2006 Oct; 26(19):7331-41. PubMed ID: 16980632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prohibitin Links Cell Cycle, Motility and Invasion in Prostate Cancer Cells.
    Koushyar S; Uysal-Onganer P; Jiang WG; Dart DA
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
    Yoon HG; Wong J
    Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.
    Kumagai J; Hofland J; Erkens-Schulze S; Dits NF; Steenbergen J; Jenster G; Homma Y; de Jong FH; van Weerden WM
    Prostate; 2013 Nov; 73(15):1636-50. PubMed ID: 23996639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
    Schweizer L; Rizzo CA; Spires TE; Platero JS; Wu Q; Lin TA; Gottardis MM; Attar RM
    BMC Cell Biol; 2008 Jan; 9():4. PubMed ID: 18218096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
    Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
    Shi XB; Xue L; Zou JX; Gandour-Edwards R; Chen H; deVere White RW
    Prostate; 2008 Dec; 68(16):1816-26. PubMed ID: 18780293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ING3 promotes prostate cancer growth by activating the androgen receptor.
    Nabbi A; McClurg UL; Thalappilly S; Almami A; Mobahat M; Bismar TA; Binda O; Riabowol KT
    BMC Med; 2017 May; 15(1):103. PubMed ID: 28511652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
    Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
    Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor transcriptional activity is required for heregulin-1β-mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase.
    Jathal MK; Siddiqui S; Vasilatis DM; Durbin Johnson BP; Drake C; Mooso BA; D'Abronzo LS; Batra N; Mudryj M; Ghosh PM
    J Biol Chem; 2023 Aug; 299(8):104973. PubMed ID: 37380074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
    Weber H; Ruoff R; Garabedian MJ
    PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.